Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 12/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | CCNK | O75909 | 3/20 | 0.46 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10241782 | 0.92 | CCNT1 (0.54) | CDK9CCNT1ABL1CCNKPIP5K1C | |
| SCHEMBL10241834 | 0.92 | CCNT1 (0.54) | CDK9CCNT1ABL1CCNKPIP5K1C | |
| SCHEMBL10241795 | 0.91 | CDK9 (0.51) | CDK9CCNT1ABL1CCNKPIP5K1C | |
| SCHEMBL1949728 | 0.89 | CCNT1 (0.60) | CDK9CCNT1CCNK | |
| SCHEMBL10285964 | 0.86 | CCNT1 (0.50) | CDK9CCNT1CCNK | |
| SCHEMBL10241724 | 0.85 | CDK9 (0.61) | CDK9CCNT1ABL1CCNKPIP5K1C | |
| SCHEMBL10241797 | 0.85 | CDK9 (0.51) | CDK9CCNT1ABL1CCNK | |
| SCHEMBL10241799 | 0.85 | CDK9 (0.51) | CDK9CCNT1ABL1CCNK | |
| SCHEMBL10241767 | 0.84 | CDK9 (0.55) | CDK9CCNT1ABL1CCNK | |
| SCHEMBL10241704 | 0.84 | CDK9 (0.55) | CDK9CCNT1ABL1CCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | PFISTER KEITH B (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011026917-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | CDK2, CDK1, CDK6 | CDK9 6/4885CCNT1 80/4885ABL1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.